Interestingly, Vela et al., described that up to 65% MALT lymphomas harbored mutations of NF-κB compounds, raising the possibility of precision therapy with BCR inhibitors in refractory cases to conventional treatment. The gene discussed is NFKB1; the disease is MALT lymphoma.